News >

Nivolumab/Ipilimumab Combo Misses Primary Endpoint in Phase III SCLC Trial

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 26, 2018

lung cancer
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve overall survival (OS) versus placebo as a maintenance therapy for patients with extensive-stage small cell lung cancer (SCLC) without disease progression following frontline platinum-based chemotherapy, missing the primary endpoint of the phase III CheckMate-451 trial.

The median DOR was not yet reached with single-agent nivolumab. In the N3/I1 arm, the median DOR was 4.4 months (95% CI, 3.7-not reached), and was 7.7 months (95% CI, 4.0-not reached) in the N1/I3 group.

References

  1. Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol. 2016;34 (suppl; abstr 100).
  2. Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016:17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Community Practice Connections™: 3rd Annual School of Gastrointestinal Oncology® (SOGO®)Jun 29, 20191.5
Publication Bottom Border
Border Publication
x